Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients

Osteoporosis International

Volumn 22, Issue 11, 2011, Pages 2847-2855

  Neuner, J M ^a   Yen, T W ^a   Sparapani, R A ^a   Laud, P W ^a   Nattinger, A B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Breast cancer; Hip fracture; Medication associated osteoporosis

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; TAMOXIFEN;

AGED; ALGORITHM; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVOR; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HIP FRACTURE; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HIP FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PROSPECTIVE STUDIES; RISK FACTORS; TAMOXIFEN;

EID: 80755163585     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1493-x     Document Type: Article

References (46)

1. PE Goss JN Ingle S Martino, et al. 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer New England Journal of Medicine 349 1793 1802 14551341 10.1056/NEJMoa032312 1:CAS:528:DC%2BD3sXosl2gtbc%3D [see comment] (Pubitemid 37362955)
2. AS Coates A Keshaviah B Thurlimann, et al. 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 Journal of Clinical Oncology 25 486 492 17200148 10.1200/JCO.2006.08.8617 1:CAS:528:DC%2BD2sXivF2mt7Y%3D [see comment] (Pubitemid 350002953)
3. RC Coombes LS Kilburn CF Snowdon, et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial The Lancet 369 559 570 10.1016/S0140-6736(07)60200-1 1:CAS:528:DC%2BD2sXhvVGgsro%3D
4. R Jakesz W Jonat M Gnant, et al. 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial The Lancet 366 455 10.1016/S0140-6736(05)67059-6 1:CAS:528:DC%2BD2MXntVeisLw%3D (Pubitemid 41111693)
5. A Howell J Cuzick M Baum, et al. 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer Lancet 365 60 62 15639680 10.1016/S0140-6736(05) 74803-0 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D [see comment]
6. VH Murthy HM Krumholz CP Gross 2004 Participation in cancer clinical trials: race-, sex-, and age-based disparities JAMA 291 2720 2726 15187053 10.1001/jama.291.22.2720 1:CAS:528:DC%2BD2cXkvVeqsL4%3D (Pubitemid 38725421)
7. JH Lewis ML Kilgore DP Goldman, et al. 2003 Participation of patients 65 years of age or older in cancer clinical trials J Clin Oncol 21 1383 1389 12663731 10.1200/JCO.2003.08.010 (Pubitemid 46606420)
8. F Boccardo A Rubagotti M Puntoni, et al. 2005 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial J Clin Oncol 23 5138 5147 16009955 10.1200/JCO.2005.04.120 1:CAS:528:DC%2BD2MXpsFWmtb4%3D (Pubitemid 46224022)
9. M Baum AU Budzar J Cuzick, et al. 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139 12090977 10.1016/S0140-6736(02)09088-8 1:CAS:528:DC%2BD38XkslGhsLY%3D [see comment][erratum appears in Lancet 2002 Nov 9;360(9344):1520] (Pubitemid 34694019)
10. RC Coombes E Hall LJ Gibson, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 15014181 10.1056/NEJMoa040331 1:CAS:528:DC%2BD2cXitV2qtbc%3D (Pubitemid 38298988)
11. D Crivellari Z Sun AS Coates, et al. 2008 Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the big 1-98 trial Journal of Clinical Oncology 26 1972 1979 18332471 10.1200/JCO.2007.14.0459 1:CAS:528:DC%2BD1cXlvFaqs78%3D
12. U.S. Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. Office of the Surgeon General, U.S. Department of Health and Human Services, Rockville
13. C Cooper LJ Melton 1992 Epidemiology of osteoporosis Trends Endocrinol Metab 3 224 229 18407104 10.1016/1043-2760(92)90032-V 1:STN:280: DC%2BD1c3kslGrsg%3D%3D
14. TA Leibson CL SE Gabriel JE Ransom LJ Melton 2002 Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study J Am Geriatr Soc 50 1644 1650 12366617 10.1046/j.1532-5415.2002.50455.x (Pubitemid 35192535)
15. T Powles T Hickish J Kanis, et al. 1996 Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women J Clin Oncol 14 78 84 8558225 1:CAS:528:DyaK28XhtVOjt74%3D (Pubitemid 26022463)
16. RR Love RB Mazess HS Barden, et al. 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer New England Journal of Medicine 326 852 856 1542321 10.1056/NEJM199203263261302 1:STN:280: DyaK387nvVaqtA%3D%3D
17. B Kristensen B Ejlertsen P Dalgaard, et al. 1994 Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study Journal of Clinical Oncology 12 992 997 8164053 1:STN:280:DyaK2c3hs12msw%3D%3D (Pubitemid 24145328)
18. PE Lonning J Geisler LE Krag, et al. 2005 Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer J Clin Oncol 23 5126 5137 15983390 10.1200/JCO.2005.07.097 (Pubitemid 46224021)
19. Early Breast Cancer Trialists Collaborate Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451 1467 10.1016/S0140-6736(97)11423-4 (Pubitemid 28227036)
20. LE Pezzin M ONiel AB Nattinger 2009 The economic consequences of breast cancer adjuvant hormonal treatments J Gen Intern Med 24 Suppl 2 446 450 10.1007/s11606-009-1079-5
21. T Yen X Fan R Sparapani P Laud A Walker A Nattinger 2009 A contemporary, population-based study of lymphedema risk factors in older women with breast cancer Ann Surg Oncol 16 979 988 19194754 10.1245/s10434-009-0347-2
22. AB Nattinger PW Laud R Bajorunaite RA Sparapani JL Freeman 2004 An algorithm for the use of Medicare claims data to identify women with incident breast cancer Health Services Research 39 1733 1749 15533184 10.1111/j.1475-6773.2004.00315.x (Pubitemid 39601249)
23. AP Nattinger LE Pezzin RA Sparapani JM Neuner TK King PW Laud 2010 Heightened attention to medical privacy: challenges for unbiased sample recruitment, and one solution Am J Epidemiol 172 637 644 20660123 10.1093/aje/kwq220
24. JM Neuner X Zhang R Sparapani PW Laud AB Nattinger 2007 Racial and socioeconomic disparities in bone density testing before and after hip fracture J Gen Intern Med 22 123 145 10.1007/s11606-007-0217-1 (Pubitemid 47247292)
25. WA Ray MR Griffin RL Fought ML Adams 1992 Identification of fractures from computerized Medicare files J Clin Epidemiol 45 703 714 1619449 10.1016/0895-4356(92)90047-Q 1:STN:280:DyaK38zhsl2lug%3D%3D
26. JR Curtis AS Mudano DH Solomon J Xi ME Melton KG Saag 2009 Identification and validation of vertebral compression fractures using administrative claims data Medical Care 47 69 72 19106733 10.1097/MLR.0b013e3181808c05
27. Z Chen, et al. 2004 Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Womens Health Initiative observational study and clinical trials Menopause 11 264 274 15167305 10.1097/01.GME.0000094210.15096.FD (Pubitemid 40362180)
28. ES Siris PD Miller E Barrett-Connor, et al. 2001 Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment JAMA 286 2815 2822 11735756 10.1001/jama.286.22.2815 1:STN:280:DC%2BD3MjgtVGmug%3D%3D (Pubitemid 33126923)
29. CN Klabunde JM Legler JL Warren LM Baldwin D Schrag 2007 A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients Ann Epidemiol 17 584 590 17531502 10.1016/j.annepidem.2007.03.011 (Pubitemid 47096709)
30. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists Group JF Forbes J Cuzick A Buzdar A Howell JS Tobias M Baum 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 18083636 10.1016/S1470-2045(07) 70385-6
31. SR Cummings 1995 Risk factors for hip fracture in white women N Engl J Med 322 767 773 10.1056/NEJM199503233321202
32. E Barrett-Connor ES Siris LE Wehren, et al. 2005 Osteoporosis and fracture risk in women of different ethnic groups Journal of Bone & Mineral Research 20 185 194 10.1359/JBMR.041007
33. B Fisher JP Costantino DL Wickerham, et al. 1998 Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study Journal of the National Cancer Institute 90 1371 1388 9747868 10.1093/jnci/90.18.1371 1:CAS:528:DyaK1cXmtlelurs%3D [see comment] (Pubitemid 28439961)
34. B Fisher JP Costantino DL Wickerham, et al. 2005 Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study Journal of the National Cancer Institute 97 1652 1662 16288118 10.1093/jnci/dji372 1:CAS:528:DC%2BD2MXht1entb7L (Pubitemid 41672231)
35. B Kristensen B Ejlertsen HT Mouridsen KW Andersen JB Lauritzen 1996 Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen Breast Cancer Res Treat 39 321 326 8877012 10.1007/BF01806160 1:CAS:528:DyaK28XlvVCqtLc%3D (Pubitemid 26278947)
36. EA Perez RG Josse KI Pritchard, et al. 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 J Clin Oncol 24 3629 3635 16822845 10.1200/JCO.2005.05.4882 1:CAS:528: DC%2BD28XovVSjsLc%3D (Pubitemid 46630537)
37. LJ Melton Iii CS Crowson WM OFallon 1999 Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time Osteoporosis International 9 29 37 10.1007/s001980050113 (Pubitemid 29086162)
38. A Brufsky N Bundred R Coleman, et al. 2008 Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole Oncologist 13 503 514 18515735 10.1634/theoncologist.2007-0206 1:CAS:528:DC%2BD1cXotFait70%3D (Pubitemid 351872868)
39. SL Greenspan A Brufsky BC Lembersky, et al. 2008 Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial J Clin Oncol 26 2644 2652 18427147 10.1200/JCO.2007.15.2967 1:CAS:528:DC%2BD1cXnvVOhsL8%3D
40. A Brufsky WG Harker JT Beck, et al. 2007 Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer Journal of Clinical Oncology 25 829 836 17159193 10.1200/JCO.2005.05.3744 1:CAS:528:DC%2BD2sXjvVKmtL0%3D (Pubitemid 350002883)
41. S-B Woo JW Hellstein JR Kalmar 2006 Systematic review: bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 753 761 16702591 1:CAS:528:DC%2BD28XlsFKhs70%3D (Pubitemid 46780635)
42. KW Lyles CS Colon-Emeric JS Magaziner, et al. 2007 Zoledronic acid and clinical fractures and mortality after hip fracture New Engl J Med 357 1799 1809 17878149 10.1056/NEJMoa074941 1:CAS:528:DC%2BD2sXht1Kit7nN (Pubitemid 350044800)
43. SR Heckbert G Li SR Cummings NL Smith BM Psaty 2008 Use of alendronate and risk of incident atrial fibrillation in women Archives of Internal Medicine 168 826 831 18443257 10.1001/archinte.168.8.826 1:CAS:528:DC%2BD1cXmtFSrsLk%3D (Pubitemid 351649266)
44. DK Wysowski 2009 Reports of esophageal cancer with oral bisphosphonate use New Engl J Med 360 89 90 19118315 10.1056/NEJMc0808738 1:CAS:528: DC%2BD1MXitVShug%3D%3D
45. BE Hillner 2004 Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer Cancer 101 1311 1322 15368322 10.1002/cncr.20492 (Pubitemid 39180386)
46. GY Locker R Mansel D Cella, et al. 2007 Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial Breast Cancer Res Treat 106 229 238 17245540 10.1007/s10549-006-9483-6 1:CAS:528:DC%2BD2sXht1Cgt7fL (Pubitemid 350045007)